10-Q: Aspira Womens Health Faces Going Concern Doubt Amid Nasdaq Delisting

Aspira Womens Health Inc. reported continued net losses and substantial doubt about its ability to continue as a going concern, alongside a Nasdaq delisting and termination of a key government funding contract.

Summary

• Aspira Womens Health Inc. reported a net loss of $4.9 million for Q3 2025, an increase from $3.5 million in Q3 2024, and a net loss of $9.4 million for the nine months ended September 30, 2025, an improvement from $11.7 million in the same period of 2024.
• The company's common stock was delisted from Nasdaq on April 15, 2025, and now trades on the OTC QX Best Market under the symbol AWHL.
• Substantial doubt exists about the company's ability to continue as a going concern within one year due to significant net losses and negative cash flows from operations since inception, with an accumulated deficit of $540.8 million as of September 30, 2025.
• The Advanced Research Projects Agency for Health (ARPA-H) terminated a $10 million contract award on June 9, 2025, after the company failed to meet Milestone 3 specifications for its ENDOinform development program.
• Product revenue increased by 2% to $2.3 million for Q3 2025 and $7.0 million for the nine months ended September 30, 2025, compared to the respective prior periods, driven by an increase in Average Unit Price (AUP).
• OvaSuite test volume decreased by 5% to 5,727 tests in Q3 2025 and by 6% to 17,134 tests for the nine months ended September 30, 2025, primarily due to a reduced field sales headcount.
• Operating expenses significantly decreased, with sales and marketing down 68% in Q3 2025 and 60% year-to-date, and general and administrative expenses down 25% in Q3 2025 and 21% year-to-date, reflecting cost-cutting measures and salesforce rebalancing.
• The company received $1.5 million from ARPA-H (Milestone 2) and $1.013 million in Employee Retention Tax Credits during the nine months ended September 30, 2025, contributing to other income.
• A material weakness in internal control over financial reporting related to complex financial transactions (warrant inducement and government grant) was identified and continues to exist as of September 30, 2025.
• The company raised approximately $2.9 million in gross proceeds from a September 2025 Private Placement Offering and $3.48 million in gross proceeds from its 2024 At the Market Offering Agreement during the nine months ended September 30, 2025.

Sentiment

Score: 2

Explanation: The company faces severe financial challenges, including a going concern warning, Nasdaq delisting, and termination of a significant government contract. While there are some operational improvements and cost reductions, the overall financial health and future viability are highly uncertain, leading to a very negative sentiment.

Positives

• Product revenue increased by 2% for both the three and nine months ended September 30, 2025, compared to the prior year periods, reaching $2.3 million and $7.0 million, respectively.
• Gross profit margin for product revenue increased to 64.1% for the nine months ended September 30, 2025, up from 58.4% in the prior year, partly due to a one-time credit related to phlebotomy expenses.
• Operating expenses saw significant reductions, with sales and marketing expenses decreasing by 68% ($1.46 million) in Q3 2025 and 60% ($3.72 million) year-to-date, and general and administrative expenses decreasing by 25% ($508,000) in Q3 2025 and 21% ($1.66 million) year-to-date.
• Loss from operations decreased by 58% ($2.165 million) in Q3 2025 and 48% ($6.218 million) year-to-date, indicating improved operational efficiency.
• Net loss for the nine months ended September 30, 2025, decreased by 20% ($2.295 million) to $9.411 million, compared to $11.706 million in the prior year.
• Net loss per share improved to $(0.13) in Q3 2025 from $(0.23) in Q3 2024, and to $(0.30) year-to-date from $(0.88) in the prior year, partly due to increased share count.
• Cash and cash equivalents increased to $3.809 million as of September 30, 2025, from $1.769 million at December 31, 2024.
• Net cash used in operating activities significantly decreased to $5.048 million for the nine months ended September 30, 2025, from $11.092 million in the prior year.
• The company rebalanced its salesforce, resulting in a 167% increase in sales per full-time equivalent salesperson in Q3 2025 compared to Q3 2024, and implemented a revenue-based compensation plan.
• Strategic initiatives include integrating OvaSuite tests with health systems (e.g., O-RADS 4 referrals) and launching the Dorsata Adnexal Mass Workflow module to large provider groups.
• The OvaWatch test's features were expanded in Q2 2024 for longitudinal monitoring, increasing its addressable market tenfold to between 2 and 4 million tests per year.
• Aspira Labs holds ISO 13485 certification, a widely accepted standard for medical devices.

Negatives

• The company reported a net loss of $4.892 million for the three months ended September 30, 2025, an increase of 38% from $3.547 million in the same period of 2024.
• There is substantial doubt about the company's ability to continue as a going concern within one year due to significant accumulated deficit ($540.8 million) and historical negative cash flows from operations.
• The company was delisted from Nasdaq on April 15, 2025, due to failure to meet the minimum $2.5 million stockholders' equity requirement, and now trades on the OTC QX Best Market.
• The Advanced Research Projects Agency for Health (ARPA-H) terminated a $10 million contract award on June 9, 2025, for the ENDOinform development program, due to the company not meeting Milestone 3 specifications, resulting in a loss of potential future funding.
• OvaSuite test volume decreased by 5% in Q3 2025 and 6% year-to-date, primarily attributed to a reduced field sales headcount.
• The change in fair value of warrant liabilities resulted in a significant expense of $4.309 million in Q3 2025 and $4.012 million year-to-date, negatively impacting net loss.
• A loss of $1.198 million was recognized upon the issuance of Convertible Notes carried at fair value for the nine months ended September 30, 2025.
• The 2025 Equity Line of Credit Agreement with Triton Funds L.P. for up to $2.0 million expired on September 30, 2025, and the company opted not to renew it.
• The 2023 Equity Line of Credit Agreement with Lincoln Park Capital Fund, LLC, with $1.7 million remaining availability, is currently inaccessible due to the Nasdaq delisting.
• The company's disclosure controls and procedures were deemed not effective as of September 30, 2025, due to a material weakness in internal control over financial reporting related to complex financial transactions.

Risks

• Substantial doubt about the company's ability to continue as a going concern within one year due to significant net losses and negative cash flows from operations since inception.
• Inability to raise additional capital through equity offerings, debt financings, or other sources on acceptable terms, which could materially adversely affect business operations.
• The company's common stock was delisted from Nasdaq, potentially impacting liquidity and investor confidence.
• Termination of the ARPA-H contract award for the ENDOinform development program means a loss of up to $6.5 million in potential future funding.
• A material weakness in internal control over financial reporting related to complex financial transactions continues to exist, indicating a risk of misstatements in financial reporting.
• The DECD loan agreement includes a condition that if the company fails to maintain its Connecticut operations through March 22, 2026, the DECD may require early repayment of a portion or all of the loan plus a 5% penalty.
• Reliance on product sales and licensing as the only material, recurring source of cash for the remainder of 2025, with no assurance of achieving or sustaining profitability or positive cash flow.
• The company's ability to use its net operating loss (NOL) carryforwards to offset future taxable income is restricted due to past ownership change limitations (Section 382 of the Internal Revenue Code).

Future Outlook

The company plans to broaden its commercial focus to the differential diagnosis of various gynecologic diseases, including endometriosis and benign pelvic mass monitoring, through non-invasive, AI-powered tests. It expects to continue commercializing existing and new technology via in-house and distributed pathways, aiming to raise public awareness of Ova1Plus's diagnostic superiority and expand access to tests for Medicaid patients. The product pipeline includes ENDOinform for endometriosis and OVAinform for ovarian cancer, with plans to expand OVAinform's indication to include asymptomatic women at elevated risk. The company expects research and development expenses to increase modestly in Q4 2025, while sales and marketing and general and administrative expenses are expected to remain flat or decrease, respectively. The company anticipates continued net losses and negative cash flows from operations for the remainder of 2025 and expects to need to raise additional capital to fund operations.

Management Comments

• Management expects cash from product sales and licensing to be the company's only material, recurring source of cash in 2025.
• Management expects to continue to incur a net loss and negative cash flows from operations for the remainder of 2025.
• Management believes the proliferation of commercially available and in-development therapeutics for the treatment of endometriosis will create a significant demand for a non-invasive diagnostic.
• Management believes the addressable market for our tests has increased to between 2 and 4 million tests per year due to the successful expansion of the OvaWatch mass monitoring feature.
• Management believes there is utility in expanding the OVAinform indication to include asymptomatic women at elevated risk due to genetic risk or first-degree relatives with ovarian cancer, which will increase the addressable market to 2.8 million women.
• Management believes the change in how we incentivize reps will steer better business and targeting by rewarding sales reps for selling business that is reimbursed well instead of compensating for selling business regardless of our ability to get paid.
• Management believes the Dorsata Adnexal Mass Workflow tool will be integral in our ability to surface our tests within providers' workflows and continue to gain adoption across large networks of physicians.

Industry Context

Aspira Womens Health operates in the highly competitive and rapidly evolving diagnostic testing market for gynecologic diseases. The company is focusing on non-invasive, AI-powered tests for ovarian cancer and endometriosis, addressing significant unmet needs. The expansion of OvaWatch's addressable market and the development of ENDOinform and OVAinform align with a broader industry trend towards personalized medicine and early, non-invasive diagnostics. The termination of the ARPA-H contract highlights the challenges in securing government funding for late-stage health solutions, while the Nasdaq delisting underscores the financial pressures faced by smaller, growth-stage diagnostic companies. The company's strategy to integrate with health systems and leverage digital workflows (Dorsata) reflects efforts to improve market penetration and physician adoption in a fragmented healthcare landscape.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any legal proceeding, the adverse outcome of which would have a material adverse effect on its financial position or results of operations as of September 30, 2025.

Related Party Transactions

• The company has a consulting agreement with Biodesix, Inc., where Jack Schuler, a beneficial owner of more than 5% of Aspira's stock, is also a beneficial owner of more than 10% of Biodesix's stock. $125,000 in costs have been recorded as research and development expense under this agreement.
• Purchasers in the March 2025 Private Placement, who are existing accredited shareholders, are entitled to nominate three representatives to the company's board of directors. Jeffrey Cohen, M.D. and John Fraser were appointed as directors following this agreement.

Stakeholder Impact

• Shareholders face significant dilution from recent and potential future equity offerings, and the Nasdaq delisting may reduce liquidity and investor confidence.
• Employees in sales roles have experienced a rebalance and reduction in field sales headcount in non-profitable markets, though sales efficiency per salesperson has increased.
• Customers (physicians and patients) may benefit from expanded product features (OvaWatch) and improved access through health system integrations and digital workflow tools (Dorsata).
• Creditors, specifically the State of Connecticut Department of Economic and Community Development (DECD), have granted loan deferrals, indicating financial difficulties for the company, and face risks if the company fails to maintain Connecticut operations.
• The termination of the ARPA-H contract impacts the company's ability to fund the ENDOinform development program, potentially delaying or altering future product availability for patients.

Next Steps

• Continue to work on the design, development, and commercial launch of the ENDOinform test despite the ARPA-H contract termination.
• Increase patient sample testing to refine the algorithm for the expanded utility of OVAinform.
• Focus on revenue-generating payers to increase revenue in the fourth quarter of 2025.
• Continue remediation activities to address the material weakness in internal control over financial reporting, including retaining outside accounting assistance.
• Seek additional capital through various sources, including equity offerings, debt financings, and strategic alliances, to fund operations and meet capital requirements.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by a 'substantial doubt about its ability to continue as a going concern' within the next year. This fundamental risk is compounded by the Nasdaq delisting, which limits access to capital markets and reduces liquidity, and the termination of a significant ARPA-H government funding contract, which removes a crucial source of non-dilutive capital for product development. While there are some operational improvements, such as increased sales efficiency and gross margin, these are overshadowed by persistent net losses, negative cash flow from operations, and a material weakness in internal controls. The company's reliance on further capital raises, with no assurance of availability on acceptable terms, makes it a highly speculative and risky investment. A seasoned investor would likely view these cumulative factors as strong indicators to exit or avoid the stock.

Keywords

Womens Health, Diagnostic Tests, Ovarian Cancer, Endometriosis, OvaSuite, Ova1Plus, OvaWatch, ENDOinform, OVAinform, Biomarkers, AI-powered tests, CLIA laboratory, SEC Filing, 10-Q, Going Concern, Nasdaq Delisting, Capital Raise, Medical Devices, Biotechnology, Healthcare Diagnostics